Approved Sickle Cell Drug Fails to Beat Placebo in Trial

[ad_1]

(MedPage Today) — Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
Adjusted annualized rate of vaso-occlusive crises leading to healthcare visits was 2.49 with the standard…

[ad_2]

Source link : https://www.medpagetoday.com/hematologyoncology/hematology/114658

Author :

Publish date : 2025-03-14 16:13:00

Copyright for syndicated content belongs to the linked Source.